Search

Displaying results 3121 - 3130 of 10000 in total
  1. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. … DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications.

  2. Drug

    Menthyl salicylate

    go.drugbank.com/drugs/DB11201
    Approved

    Menthyl salicylate is an ester of menthol and salicylic acid [L2808]. This product is used to treat minor aches and pains of the muscles/joints (e.g., arthritis, backache, sprains) [L2810].

  3. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label].

    Salts: 1-palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)), sodium saltSynonyms: l-Alpha-1-palmitoyl-2-oleoylglycerophosphoglycerol, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
  4. Drug

    Crovalimab

    go.drugbank.com/drugs/DB16128
    ApprovedInvestigational

    [A263958] It soon gained its approval in Japan in the next month,[A263958] and in the USA in June of the same year. … [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

  5. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p16) … An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically.

  6. Drug

    Benfotiamine

    go.drugbank.com/drugs/DB11748
    ApprovedInvestigationalWithdrawn

    Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Dihydroergocristine

    go.drugbank.com/drugs/DB13345
    Approved

    [L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.

  8. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    [A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor … Sunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.

    Synonyms: 2-Propenamide, N-[5-[[4-[[5-chloro-4-fluoro-2-(1-hydroxy-1- methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]-, N-{5-[(4-{[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino}pyrimidin-2-yl)amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl}prop-2-enamide
  9. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). … [A253292,A253297,L43557] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended tabelecleucel be granted marketing authorization for the treatment of adult and

  10. Drug

    Grepafloxacin

    go.drugbank.com/drugs/DB00365
    ApprovedWithdrawn

    Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States … Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections.